September 2019 A shelf registration statement has been filed with the United States Securities and Exchange Commission, but has not yet become effective. Any offers, solicitations of offers to buy, or sales of these secu

A shelf registration statement has been

filed with the United States Securities and Exchange Commission, but has not yet become effective. Any offers, solicitations of

offers to buy, or sales of these securities will only be made once the shelf registration statement has been declared effective

by the United States Securities and Exchange Commission, including any prospectuses and prospectus supplements. These securities

may not be sold, nor may offers to buy be accepted, prior to the time that the shelf registration statement becomes effective.

This press release shall not constitute

an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which

an offer, solicitation or sale would be unlawful prior to registration and qualification under the securities law of such jurisdiction.

("Midatech" or the "Company")

Midatech Announces Filing of U.S. Shelf

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:

MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today

announced that the Company has filed a "universal" shelf registration statement on Form F-3 with the U.S. Securities

and Exchange Commission (the "SEC"). The filing of a shelf registration statement,

a common practice by NASDAQ-listed companies, is intended to provide the Company with more timely and efficient access to the U.S.

Once declared effective by the SEC, the

shelf registration statement, which can remain effective for up to three years, will enable the Company to offer, issue and sell,

in one or more offerings at any time (as long as the shelf registration statement remains effective), up to an aggregate of $50

million of ordinary shares, including American Depositary Shares ("ADSs", where each ADS represents 20 ordinary shares),

warrants, and a combination of such securities, separately or as units (collectively, the "Securities"). The specifics

of any future offering, including the prices and terms of any Securities offered by the Company, would be determined at the time

of any such offering and would be described in detail in a prospectus supplement filed in connection with such offering.

A copy of the base prospectus included

in the shelf registration statement may be obtained on the SEC's website at www.sec.gov. The filing of the shelf registration statement

does not affect the statutory pre-emption rights of shareholders in the Company.

For more information, please contact:

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States. All statements contained in this press release that do not relate to matters of historical fact should be

considered forward-looking statements, including, but not limited to, statements regarding the shelf registration statement providing

Midatech timely and efficient access to the U.S. financial markets and the period of effectiveness of the shelf registration statement.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise